Author:
Wilkerson Myra L.,Cheng Liang
Publisher
Springer International Publishing
Reference211 articles.
1. Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, et al. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol. 1995;26(9):970–8.
2. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16(3):187–91.
3. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H. Dimopoulos. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol. 1998;29(2):146–54.
4. Southgate J, Harnden P, Trejdosiewicz LK. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol. 1999;14(2):657–64.
5. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074–8.